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Abstract: Sex hormones play important roles in the onset and progression of several cancers, such as
breast, ovarian, and prostate cancer. Although drugs targeting sex hormone function are useful in
treating cancer, tumors often develop resistance. Thus, we need to define the downstream effectors of
sex hormones in order to develop new treatment strategies for these cancers. Recent studies unearthed
one potential mediator of steroid hormone action in tumors: growth regulation by estrogen in breast
cancer 1 (GREB1). GREB1 is an early estrogen-responsive gene, and its expression is correlated with
estrogen levels in breast cancer patients. Additionally, GREB1 responds to androgen in prostate cancer
cells, and can stimulate the proliferation of breast, ovarian, and prostate cancer cells. Recent studies
have shown that GREB1 also responds to progesterone in human endometrial cells, suggesting that
GREB1 is a pan steroid-responsive gene. This mini-review examines evidence that GREB1 participates
in several hormone-dependent cancers and could be targeted to treat these cancers.
Keywords: GREB1; steroid hormone; estrogen; progesterone; androgen; breast cancer; ovarian cancer;
prostate cancer
1. Hormone-Dependent Cancers
Steroid hormones are a selective branch of signaling molecules, which are biosynthesized from
cholesterol derivatives in the mitochondria [1]. Steroid hormones are broadly classified into two
subcategories based on their biosynthesis: corticosteroids and sex steroids [2]. Produced in the
adrenal cortex, corticosteroids regulate a wide array of physiological processes, including immune,
inflammatory, and stress responses. Notable corticosteroids include the glucocorticoid, hydrocortisone,
mineralocorticoid, and aldosterone hormones. Produced in the gonads, hormones in the sex steroid
class (i.e., estrogen, progesterone, and androgen) are vital for the development and maintenance of
sexual characteristics as well as for general reproductive function [2]. Despite their role in normal
reproductive development, sex steroids have also co-opted to play a role in the development and
progression of several human cancers.
Sex-steroid hormones exert their physiologic and pathological function through their cognate
receptors (steroid receptors), including estrogen receptors (ERs), androgen receptors (ARs),
and progesterone receptors (PRs). All of these receptors belong to the nuclear receptor superfamily
and consist of tissue-specific subtypes [3,4]. For example, produced differentially in various tissues,
two distinct receptors, ERα and ERβ, exert distinct physiological and pathophysiological functions.
ERα is the predominant receptor in the uterus, breasts, and ovaries, whereas ERβ plays significant
roles in the bone, kidney, and cardiovascular systems [5]. Importantly, numerous findings revealed a
key role for these hormones and their cognate receptors in human cancer onset and progression [4,6,7].
For example, the majority of breast cancer cell lines express the estrogen receptor [8–10], and the
first-line therapy Tamoxifen selectively antagonizes ER [11,12]. Likewise, the risk of epithelial ovarian
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cancer is increased by long-term exposure to estrogen, as occurs in early menarche, late menopause,
and in the context of hormone replacement therapy [13,14]. Indeed, one study of 394 serous
epithelial ovarian cancer patients reported that 86% of tumors were ER-positive [15]. Moreover,
when ER-positive epithelial ovarian cancer cells were implanted in the peritoneal cavity of mice,
estrogen significantly increased tumorigenesis, promoted lymph node metastasis, and decreased
survival [16,17]. Additionally, prostate cancer initiation and progression is regulated by androgen [18].
Thus, common treatment options for prostate cancer include orchiectomy and hormonal therapy,
both of which function by restricting the androgen/androgen receptor interaction [4].
Although anti-hormonal therapeutics have been used to treat these hormone-dependent cancers,
such drugs are often ineffective in the long term as the cancers develop drug resistance. For example,
Tamoxifen, a selective estrogen receptor modulator (SERM), is widely used in breast cancer therapy [11].
However, about one-third of patients will acquire drug resistance and suffer from tumor recurrence [19].
Overcoming this challenge will require defining the mechanisms by which hormones drive these
cancers and identifying new therapeutic targets.
2. Nuclear Receptor Coactivators in Hormone-Dependent Cancers
Nuclear receptors, including ER, AR, and PR, share a common mechanism of regulation. Upon the
binding of a hormone to its cognate receptors, the receptor undergoes a conformational change to
expose the hormone response element binding site and form a homodimer [5]. Upon interaction of the
receptor with a coactivator, the homodimer binds to hormone response elements and modulates the
transcription of hormone-dependent genes [3,20] (Figure 1).
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Figure 1. Model of the classic hormone-signaling pathway. The hormone enters the cell andbinds to
a hormone receptor (HR). The arrows represent steps involved in activation of HR by its hormone.
The HR forms a homodimer, undergoes a structural change to expose the hormone response element
(HRE) binding domain, and enters the nucleus. Then, in conjunction with coactivators, HR binds an
HRE to modulate the transcription of downstream genes such as GREB1. The arrows represent steps
involved in activation of HR by its hormone.
The steroid receptor coactivator (SRC) family was the first identified coactivator class
for nuclear receptors [21]. Three members, SRC-1, SRC-2, an SRC-3, are part of this key
coactivator family. All three isoforms share conserved domains, including the N-terminal basic
helix-loop-helix-Per/ARNT/Sim (b-HLH-PAS), the central nuclear receptor interacting domain,
a two C-terminal activation domains, AD1 and AD2 [22]. The N-termi al b-HLH-PAS domain is
highly conserved in the SRC family. The central nuclear receptor interacting domain contains three
Leu-X-X-Leu-Leu (LXXLL) motifs, which are crucial for the coactivator’s function toward uclear
receptors. The X-ray crystal structure shows that LXXLL motifs have a two-turn α-helical conformation.
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The three conserved leucines align on the face of the helix and fit into the hydrophobic channels of the
ligand-binding domain (LBD) on nuclear receptors [23]. The C-terminal activation domain can recruit
different coactivators to modulate the transcription [22,24].
Recent advancements revealed an indispensable role for SRCs in steroid hormone-dependent
functions in hormone-dependent carcinogenesis. In hormone-dependent cancers, all three members
of the SRC family are expressed and are associated with prognosis [25–27]. In addition, SRC-1 and
SRC-3 can stimulate cancer cell proliferation and promote cancer metastasis [28,29]. The expression of
SRC-1 in breast cancer patients is associated with acquired drug resistance and relapse after endocrine
therapy [30]. Likewise, in ovarian cancer, SRC-3 is elevated in high-grade ovarian epithelial cancer
tissue [31]. SRC-3 considered as a poor prognostic factor and confers platinum resistance in ovarian
epithelial cancer [32]. In endometrial cancers, the high expression of SRC-3 mRNA correlates with
the advanced stage of cancer and poor prognosis [33]. Recent advancements highlighted a central
role for SRC members in prostate cancer cells [34]. For example, all three family members were found
to be essential for cancer cell survival and promote metastasis [35–37]. In contrast, the inhibition of
the expression of SRC-3 can improve the sensitivity of human breast cancer cell line MDA-MB-231
to histone deacetylase inhibitors [38]. Further, the downregulation of SRC-3 reduces ovarian cancer
cell migration and metastasis [31]. These aforementioned findings highlight an indispensable role for
SRCs in hormone-dependent cancer onset and progression.
Interestingly, SRC-3 is reported to interact with growth regulation by estrogen in breast cancer
1 (GREB1) and increase estrogen-induced transcription in breast cancer cell line MCF-7 cells [39].
We found that GREB1 is transcriptionally activated by SRC-2 via the progesterone–PR axis in
endometrium [40], and a novel fusion gene, GREB1-SRC-2, was detected in uterine sarcoma [41].
These evidences point out that GREB1 may play a vital role in hormone-dependent cancers. In this
review, we will argue that GREB1 is a good candidate for development of therapeutics for breast,
ovarian, prostate, and perhaps even uterine and testicular cancers.
3. GREB1 Structure and Function
GREB1 was first discovered in brain tissue [42] and later identified as an early estrogen-responsive
gene in breast cancer [43]. The GREB1 gene is highly conserved across species and is expressed in many
tissues, including the brain [42], mammary gland [43], ovary [16], prostate [44], and endometrium [40].
In humans, the GREB1 gene is located at 2p25.1, spans 108.68 kb, and contains 38 exons and
40 introns [43,45] (Figure 2). GREB1 is expressed as three distinct isoforms: GREB1a, GREB1b,
and GREB1c [43]. GREB1a is the full-length isoform, whereas variant splicing and the introduction
of early termination codons result in GREB1b and GREB1c, which terminate after exons 10 and 9,
respectively [46] (Figure 2).
Very little is known on the functional differences between these three isoforms. Much of our
understanding of the GREB1 function comes from the analysis of its protein domains. At the
C-terminus, GREB1 contains a circularly permuted superfamily II (SFII) helicase fused to a ten-eleven
translocation/J binding protein (TET/JBP) and glycosyltransferase (TAGT) domain [47] (Figure 2).
The SFII helicase is presumed to bind nucleic acids, but has no catalytic activity [47], and TAGTs can
glycosylate pyrimidines in DNA [47]. The glycosylation is a key modification observed in different
types of cancers, including breast, ovarian, and prostate cancers [48]. Glycosylation facilitates the
cell adhesion, proliferation, and metastasis of breast cancer [49]. Six glycosylated genes—FUT1,
FUCA1, POFUT1, MAN1A1, RPN1 and DPM1—are reported to be associated with the prognosis of
breast cancer [50]. Further, glycosyltransferase gene expression is correlated with the prognosis of
ER-positive breast cancer [51]. However, the importance of GREB1-mediated DNA modification is
unknown. At the N-terminus, GREB1 contains two LXXLL motifs, which are commonly found in
coactivators and mediate interactions with nuclear receptors [52,53] (Figure 2). However, the LXXLL
motifs are not necessary for GREB1 to interact with ER [46], and although all three GREB1 isoforms
bind to ER [53], they may not function as coactivators. Instead, exogenously expressed GREB1a can
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independently enhance the expression of ER target genes PS2 and SDF1, while exogenously expressed
GREB1b had no effect [46]. These findings suggest that the GREB1 isoforms might have differential
effects on ER driven gene expression.
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Figure 2. Model of growth regulation by estrogen in breast cancer 1 (GREB1) structure and transcription.
The human GREB1 gene is located on 2p25.1. Three upstream estrogen response elements (EREs) located
at−21.2,−9.5, and−1.6 kb and one androgen response element (ARE) located at−3.3 kb can modulate
GREB1 transcription. The GREB1 gene produces at least three isoforms: GREB1a (NM_014668.3→
NP_055483.2), GREB1b (NM_033090.2→ NP_149081.1), and GREB1c (NM_148903.2→ NP_683701.2),
which have alternate 5′ and 3′ UTRs. Splicing after exons 10 and 9 results in short GREB1b and GREB1c
isoforms, respectively. The GREB1a protein contains two LXXLL motifs and a superfamily II (SFII)
helicase module fused with a glycosyltransferase (TAGT) motif in the C-terminus.
4. Hormone Regulation of GREB1
The classic hormone-signaling pathway begins with a hormone binding to its cognate hormone
receptor, causing the receptor to homodimerize [5] and undergo a structural change to expose the
hormone response element binding site [54]. While the hormone-binding domain is located at the
C-terminus, the hormone response element binding domain is in the central region of the receptor.
The hormone-bound homodimer enters the nucleus where, in conjunction with a coactivator, it binds
to hormone response elements in the upstream of GREB1 and then modulates the transcription of
target genes [3,20] (Figure 1).
Several lines of evidence indicate that GREB1 is regulated by the hormones estrogen, progesterone,
and androgen [54–58]. First, GREB1 expression was markedly elevated in the mammary tissue
of female cynomolgus macaques during the pubertal stages, when estrogen levels were high,
and decreased after menopause, when estrogen levels were low [56]. Second, in breast cancer
patients, GREB1 expression correlated with estrogen levels [57]. Third, throughout women’s
reproductive years, GREB1 expression in the endometrium fluctuates in accordance with estrogen
levels [59]. Fourth, GREB1 expression increased during progesterone-mediated endometrial stromal
cell decidualization, and progesterone receptor knockdown led to a decrease in GREB1 transcript
levels [40]. Further, three estrogen response elements (EREs) [54,58] and at least one androgen
response element (ARE) [44,53] are located upstream of the GREB1 transcription start site (Figure 2).
Consistent with this, the expression of GREB1 correlated with the expression of hormone receptors in
reproductive tissues in human (Table 1). The known functions of GREB1 in reproductive cancers will
be detailed in the following sections of this review.
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Table 1. The Protein Expression of GREB1 and Hormone Receptor in Different Tissue Types.
ER: Estrogen Receptor, AR: Androgen Receptor, PR: Progesterone Receptor.
Tissue Type
and Expression
GREB1 ER AR PR
Normal Cancer Normal Cancer Normal Cancer Normal Cancer
Breast + +
ER-α + ER-α +
+ + + +ER-β − ER-β +
Ovary + +
ER-α − ER-α +
+ + − +ER-β − ER-β +
Endometrium + +
ER-α + ER-α +




ER-α + ER-α ?
+ ? + ?ER-β − ER-β ?
Prostate + +
ER-α − ER-α + − + − +ER-β − ER-β +
Testis + +
ER-α − ER-α +
+ + − +ER-β + ER-β +
+: expression; −: no expression; ?: not mentioned. (The expression of tissue is according to the data shown on the
website of human protein atlas: https://www.proteinatlas.org/).
5. Role of GREB1 in Breast Cancer
Estrogen and progesterone play a vital role in mammary gland growth and cancer
development [60]. Breast cancer is the most prevalent form of cancer in women [61]. In the mammary
gland, ERα is the predominant subclass of ER, and is expressed in the majority of breast cancer cells.
Estrogen is a key mediator in the development and progression of breast cancer [7], and several
studies indicate that ER regulates GREB1 expression. Cancer cells expressing the ER are classified
as ER-positive breast cancers [8]. In ER-positive breast cancers, the plasma level of estradiol and the
expression of ERs are positively correlated with GREB1 expression [62]. The younger (age ≤ 45 years)
group of breast cancer patients who had higher estrogen levels showed significantly higher GREB1
expression than the older (age ≥ 70 years) group [63]. Additionally, the majority of breast cancer cell
lines, including MCF-7, T-47D, and BT-474 [9,10], are ER-positive and express GREB1 at high levels.
Conversely, ER-negative breast cancer cell lines MDA-MB 231 and SUM 225 express GREB1 at lower
levels [64]. GREB1 appears to help regulate the transcription of ER target genes, as the chromatin
immunoprecipitation (ChIP) sequencing analysis of MCF-7 cells revealed that approximately 95%
of the GREB1-bound regions were also bound by ER [53]. Upon GREB1 knockdown in MCF-7 cells,
nearly half of the estrogen-responsive genes were no longer differentially expressed, and the cells
were less able to form colonies [53]. To assess the in vivo effect of estrogen on GREB1 expression,
Rae et al. ovariectomized athymic nude mice to prevent endogenous estrogen production and
implanted MCF-7 cells in the peritoneal cavity [10]. As expected, the levels of GREB1 and estrogen were
reduced upon ovariectomization. Conversely, GREB1 expression increased when exogenous estrogen
was administered. Although estrogen treatment did not affect tumor size during the 48-hour treatment
period [10], longer treatment could result in enhanced tumor growth, as suggested by in vitro work
showing that estrogen induced the proliferation of MCF-7, BT-474, and T47D cell lines [10].
Further evidence for the role of GREB1 in breast cancer comes from studies of the cells’ responses
to Tamoxifen. Breast cancer cells initially respond to Tamoxifen, which antagonizes the ER and leads
to decreased GREB1 expression [65]. However, in Tamoxifen-resistant breast cancer tissues, the GREB1
promoter becomes more methylated via the action of the histone lysine N-methyltransferase EZH2,
leading to the epigenetic downregulation of GREB1 [65].
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6. Role of GREB1 in Ovarian Cancer
GREB1 also plays a significant role in ovarian cancer, which is a gynecologic malignancy that
causes an estimated 12,700 deaths in the United States (US) alone [66]. Unlike breast tumors, where the
tissue is easily accessible for diagnostic purposes, the ovary is located deep in the pelvic cavity.
Therefore, the early detection of ovarian cancer proves difficult due to the subtle symptomology of
cancer and poor screening methods [67]. As a result, nearly 75% of ovarian cancers are diagnosed only
in later (advanced) stages of cancer [66,67]. Ovarian cancers are traditionally classified into three main
categories with additional subtypes based on their histogenesis and subsequent differentiation [68].
Sex cord stromal tumors develop in the connective tissue of the ovaries and account for approximately
5% of ovarian cancers in women. Similarly, germ cell tumors account for about 5% of ovarian cancers,
and are typically diagnosed in young women aged aroundearly 20 years. Accounting for almost
90% of cases, epithelial ovarian cancers are classified into several subtypes, of which serous tumors
are the most notable [66]. A key study reported that 86% of serous epithelial ovarian tumors are
ER-positive [15]. In vitro, estrogen can stimulate the proliferation of ER-positive ovarian cancer cell
lines [69]. Several lines of evidence point to a role for GREB1 in the progress of epithelial ovarian
cancer. In a tissue microarray analysis of ovarian cancer cases, GREB1 was expressed in 75–85%
of epithelial ovarian cancer cells [55]. Tumor xenograft studies using mouse ovarian cancer ascites
(MAS) cells with elevated GREB1 expression indicated an increase in tumor growth and reduced
median survival time [16,55]. In vitro, GREB1 knocked down in MAS cells results in decreased
proliferation and favorable morphologic changes [16,55]. These findings support a key role for GREB1
in estrogen-dependent actions in epithelial ovarian cancers.
7. Role of GREB1 in Prostate Cancer
Accounting for nearly 366,000 deaths globally per year, prostate cancer is the second most
prevalent cancer in males in the US, and the majority of cases are adenocarcinomas [70,71]. Similar to
the hormonal regulation of reproductive tract development and sexual function by estrogen in women,
androgen controls the central reproductive function in males, including the prostate [72]. The prostate
is an excretory gland that secretes prostate fluid, and the prostatic glands are androgen-dependent in
nature. The initiation and progression of prostate cancer are regulated by androgen [73]. The common
treatment options for prostate cancer include orchiectomy and hormonal-deprived therapy, both of
which function by restricting androgen/androgen receptor (AR) functions [4]. Androgen can regulate
GREB1 expression by binding to ARs, which then bind the ARE upstream of the GREB1 transcriptional
start site (Figure 2) [44]. Rae et al. showed that GREB1 was highly expressed in benign prostatic
hypertrophy, prostate cancer, and AR-positive prostatic carcinoma cell lines, and that GREB1 responded
to androgen in a dose-dependent manner. Additionally, they reported that GREB1 knockdown reduced
the proliferation of lymph node carcinoma of the prostate (LNCaP) cells [44]. Similarly, Ferreira,
et al. found that treatment with the androgen dihydrotestosterone upregulated GREB1 expression in
androgen-responsive LNCaP cells [74].
8. The Emerging Role for GREB1 in Other Hormone-Dependent Cancers
Although not as well studied as in breast, ovary, and prostate cancers, GREB1 may also
play a role in uterine and testicular cancer. The uterus is composed of the endometrium and
myometrium. Among women of reproductive age, the cyclical fluctuation of estrogen and progesterone
in the endometrium promotes the monthly proliferation, differentiation, and shedding of tissue,
which is commonly known as menstruation [72]. In the uterus, GREB1 is highly expressed in
the endometrium [59]. Throughout women’s reproductive age, GREB1 expression fluctuates in
accordance with estrogen levels [59]. Endometrial tissues under the long-term influence of estrogen
are disposed to endometrial hyperplasia and endometrial adenocarcinoma. In addition to being
regulated by estrogen, recent evidence indicates that GREB1 is regulated by progesterone in human
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endometrial cells [40]. GREB1 expression increased during progesterone-mediated endometrial stromal
cell decidualization, and progesterone receptor knockdown led to a decrease in GREB1 transcript
levels [40]. Given that endometrium exposed to estrogen in the absence of progesterone is prone to
hyperplasia and carcinogenesis [72] and that GREB1 is regulated by both hormones, it seems likely that
GREB1 contributes to endometrial cancer. One study reported a positive correlation between GREB1
expression and ERα activation in endometrial cancer [75]. Additionally, endometrial cancer appears
to overlap genetically with endometriosis [76,77], and GREB1 mRNA levels are significantly higher
in ectopic endometrium (endometriosis lesions) than in eutopic endometrium [78]. Furthermore,
single nucleotide polymorphisms around the GREB1 locus have been identified in endometriosis
patients [59,79–81]. Further, GREB1 polymorphic variants are associated with bone mineral density
in a cohort of Caucasians [82]. Low bone mineral density is a critical manifestation of osteoporosis,
and estrogen is known to control bone remodeling. Thus, future work should address the possibility
that mutations in GREB1 predispose women to hormone-related diseases including endometriosis and
postmenopausal osteoporosis.
GREB1 may also participate in uterine sarcomas, which constitute 8% of uterine corpus
cancers [83] and are derived from myometrial, mesenchymal, or undifferentiated cells [84].
Brunetti et al. reported a translocation (2;8)(p25;q13) in a patient with undifferentiated uterine sarcoma
and lung metastases. Transcriptome sequencing analysis revealed that this translocation created a
novel GREB1–nuclear receptor coactivator 2 (NCOA2) fusion gene in which the first three exons of GREB1
(NM_014668.3) were fused to exon 15 of NCOA2 (NM_001321703.1) [41]. Given that NCOA2, which is
also called SRC-2, regulates the progesterone-dependent transcriptional regulation of GREB1 in human
endometrial cells [40], additional studies are required to determine the role of this fusion gene in
endometrial cancer onset and progression.
The testes, which both produces gametes and secretes androgen [72] to maintain sexual
characteristics [85], relies on androgen signaling for many of its functions. No work has been done to
assess the role of GREB1 in testicular cancer, but some findings suggest that GREB1 participates in
testicular functions [86,87]. The Sertoli cells, which establish the blood–testis barrier in the seminiferous
tubules, express both androgen and estrogen receptors [88]. Two papers suggested that GREB1 is
expressed in mouse Sertoli cells as a result of estrogen binding to the ER [86,87]. Given these findings,
future work should be directed at assessing whether or not GREB1 participates in testicular functions
and testicular cancer.
9. Translational Relevance
Understanding the underlying mechanism of hormone actions will offer novel diagnostic and/or
treatment strategies in the clinical management of hormone-dependent cancers. Considering the
role of GREB1 in hormone-dependent cancers, GREB1 should be considered as a diagnostic and
therapeutic target. In breast cancer, Mohammed et al. found that the level of GREB1 was a favorable
prognostic factor independent of the Nottingham prognostic index, which predicts breast cancer
prognosis after surgery on the basis of lesion size, the number of involved lymph nodes, and tumor
grade [53,89]. Similarly, in ovarian cancer, the hypomethylation of GREB1 was positively correlated
with progression-free survival in ovarian cancer patients [90]. Additionally, a microarray analysis of
prostate cancer samples from 33 patients showed that high GREB1 expression was associated with
organ-confined disease, which is lower stage and a more favorable prognosis in prostate cancer [91].
It important to note that elevated expressions of GREB1 have been observed in hormone-dependent
cancers, which are more sensitive to hormone therapy than receptor-negative tumors. Therefore,
GREB1 expression in lower stage receptor-positive cancers might be more favorable toward prognosis.
The majority of higher stage tumors from the aforementioned report [91] might be receptor-negative,
which are resistant to therapy, and thus are not favorable for prognosis. Nonetheless, future work
should conduct similar studies in larger cohorts of patients from multiple hormone-dependent cancers.
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In addition to informing prognosis, the improved understanding of GREB1 may reveal novel
strategies to combat drug resistance. In Tamoxifen-resistant breast cancer tissues, the GREB1 promoter
becomes more methylated via the action of the histone lysine N-methyltransferase EZH2, leading to the
epigenetic downregulation of GREB1 [65]. EZH2-mediated histone methylation drives the epigenetic
programming in tumor cells, including breast, ovarian, and prostate cancers [92–95]. These epigenetic
changes activate multiple oncogenes and promote tumor progression and metastasis [96]. Thus, it is
plausible that GREB1 methylation confers drug resistance for hormone-dependent cancers. Based on
the aforementioned studies, strategies to target GREB1 could lead to improved hormone-dependent
cancer prognosis and treatment.
Interestingly, the expression analysis of GREB1 demonstrated in Oncomine, the Cancer Cell
Line Encyclopedia (CCLE), and protein atlas indicate that GREB1 has much wider expression than
in hormone-related organs or tissues. Generally, the expression level of GREB1 is much higher in
pathologic status than in healthy status. Thus, a small molecular inhibitor or monoclonal antibody
against GREB1 that abolishes the overexpressed level of GREB1 with minimal effect on physiological
actions would be a viable option to target GREB1. Thus, an in-depth functional analysis of GREB1 in
hormone-dependent cancers is warranted prior to targeting GREB1 in hormone-dependent cancers.
10. Conclusions and Open Questions
The pan hormone-responsive gene GREB1 plays important roles in the initiation and progression
of some sex hormone-driven cancers. However, many open questions remain, such as: (1) Do GREB1
isoforms have differential actions in hormone-dependent cancers? If so, what are the underlying
mechanisms? (2) Is GREB1 epigenetically regulated in cancer? (3) Does GREB1 function via common
or hormone-specific functions? (4) Are mutations in GREB1 associated with the occurrence of
hormone-dependent cancers? By addressing such questions, the field will be able to fully elucidate
the normal functions of GREB1, define its role in cancers, and assess its potential as a prognostic and
therapeutic target.
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ARE Androgen Response Element
b-HLH-PAS Basic Helix-Loop-Helix-Per/ARNT/Sim
CCLE Cancer Cell Line Encyclopedia
ChIP Chromatin Immunoprecipitation
ER Estrogen Receptors
ERE Estrogen Response Element
GREB1 Growth Regulation by Estrogen in Breast Cancer 1
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LBD Ligand Binding Domain
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NCOA2 Nuclear Receptor Coactivator 2
PR Progesterone Receptors
SERM Selective Estrogen Receptor Modulator
SF II Superfamily II
SRC Steroid Receptor Coactivator
TAGT TET/JBP-Associated Glycosyltransferase
TET/JBP Ten-Eleven Translocation/J Binding Protein
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